Showing posts with label relapsed. Show all posts
Showing posts with label relapsed. Show all posts
Tuesday, August 18, 2026

U.S. FDA Grants Full Approval of Kite’s Tecartus for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma

›
The U.S. Food and Drug Administration (FDA) has granted traditional (full) approval to Kite’s CAR T-cell therapy, Tecartus (brexucabtagene a...
Tuesday, July 28, 2026

FDA Approves Komzifti (ziftomenib) for the Treatment of Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

›
Kura Oncology, Inc. (Nasdaq: KURA) and Kyowa Kirin Co., Ltd. (TSE: 4151)  announced the U.S. Food and Drug Administration (FDA)   approval o...
Saturday, September 28, 2024

FDA Grants Accelerated Approval for Ojemda (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma

›
Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to deve...
Friday, March 1, 2024

FDA Approves Jaypirca (pirtobrutinib) for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma

›
Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY),  announced the U.S. Food and Drug Administration (FDA) approved  Jaypirc...
Monday, February 22, 2016

Ibrutinib ‘new standard’ for relapsed, refractory mantle cell lymphoma

›
In continuation of my update on  Ibrutinib and  Temsirolimus Temsirolimus Phase III trial findings suggest that patients with relap...
Wednesday, February 10, 2016

Role for carfilzomib in relapsed, refractory multiple myeloma treatment

›
In continuation of my update on carfilzomib Carfilzomib significantly improves outcomes in previously treated patients with relap...